Moshe Oren
Moshe Oren
Verified email at
Cited by
Cited by
Mdm2 promotes the rapid degradation of p53
Y Haupt, R Maya, A Kazaz, M Oren
Nature 387 (6630), 296-299, 1997
Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018
L Galluzzi, I Vitale, SA Aaronson, JM Abrams, D Adam, P Agostinis, ...
Cell Death & Differentiation 25 (3), 486-541, 2018
Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6
E Yonish-Rouach, D Resnftzky, J Lotem, L Sachs, A Kimchi, M Oren
Nature 352 (6333), 345-347, 1991
The first 30 years of p53: growing ever more complex
AJ Levine, M Oren
Nature reviews cancer 9 (10), 749-758, 2009
mdm2 expression is induced by wild type p53 activity.
Y Barak, T Juven, R Haffner, M Oren
The EMBO journal 12 (2), 461-468, 1993
Transcriptional activation of miR-34a contributes to p53-mediated apoptosis
N Raver-Shapira, E Marciano, E Meiri, Y Spector, N Rosenfeld, ...
Molecular cell 26 (5), 731-743, 2007
Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life
CA Finlay, PW Hinds, TH Tan, D Eliyahu, M Oren, AJ Levine
Molecular and cellular biology, 1988
Decision making by p53: life, death and cancer
M Oren
Cell Death & Differentiation 10 (4), 431-442, 2003
Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis
N Rivlin, R Brosh, M Oren, V Rotter
Genes & cancer 2 (4), 466-474, 2011
p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs
M Müller, S Wilder, D Bannasch, D Israeli, K Lehlbach, M Li-Weber, ...
The Journal of experimental medicine 188 (11), 2033-2045, 1998
Participation of p53 cellular tumour antigen in transformation of normal embryonic cells
D Eliyahu, A Raz, P Gruss, D Givol, M Oren
Nature 312 (5995), 646-649, 1984
Wild-type p53 can inhibit oncogene-mediated focus formation.
D Eliyahu, D Michalovitz, S Eliyahu, O Pinhasi-Kimhi, M Oren
Proceedings of the National Academy of Sciences 86 (22), 8763-8767, 1989
Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53
D Michalovitz, O Halevy, M Oren
Cell 62 (4), 671-680, 1990
The p53–Mdm2 module and the ubiquitin system
D Michael, M Oren
Seminars in cancer biology 13 (1), 49-58, 2003
ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage
R Maya, M Balass, ST Kim, D Shkedy, JFM Leal, O Shifman, M Moas, ...
Genes & development 15 (9), 1067-1077, 2001
Mutant p53 gain-of-function in cancer
M Oren, V Rotter
Cold Spring Harbor perspectives in biology 2 (2), a001107, 2010
Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes
L Galluzzi, SA Aaronson, J Abrams, ES Alnemri, DW Andrews, ...
Cell Death & Differentiation 16 (8), 1093-1107, 2009
Regulation of the p53 tumor suppressor protein
M Oren
Journal of Biological Chemistry 274 (51), 36031-36034, 1999
Extracellular vesicle and particle biomarkers define multiple human cancers
A Hoshino, HS Kim, L Bojmar, KE Gyan, M Cioffi, J Hernandez, ...
Cell 182 (4), 1044-1061. e18, 2020
Induction of apoptosis in HeLa cells by trans-activation-deficient p53.
Y Haupt, S Rowan, E Shaulian, KH Vousden, M Oren
Genes & development 9 (17), 2170-2183, 1995
The system can't perform the operation now. Try again later.
Articles 1–20